Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population
Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin
Event:
ESC Congress 2016
Topic:
Atrial fibrillation (AF)
Session:
Anticoagulation in atrial fibrillation II